Background Preclinical data have suggested that nintedanib, an intracellular inhibitor of
tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the …

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis
(IPF), but the disease continues to progress. More data are needed on the safety and …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, …

Background Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A
subgroup analysis of a previously published trial suggested that sildenafil may provide …

Background The efficacy and safety of nintedanib, an intracellular tyrosine kinase inhibitor,
in patients with idiopathic pulmonary fibrosis were assessed in two phase 3, placebo-…

Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary
fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by
dyspnea and loss of lung function. Methods Using pooled data from the replicate, randomized, …

Objective To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune
disease–related interstitial lung diseases (ILDs) with a progressive phenotype. Methods …

Introduction Nintedanib slows disease progression in patients with idiopathic pulmonary
fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event …